Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | PPOX | P50336 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FER | P16591 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366565 | 0.88 | LMNA (0.58) | LMNACHEK1MAPTTP53POLB | |
| SCHEMBL9967368 | 0.88 | LMNA (0.61) | LMNACHEK1MAPTTP53POLB | |
| SCHEMBL29753145 | 0.88 | LMNA (0.61) | LMNACHEK1MAPTTP53POLB | |
| SCHEMBL7878578 | 0.84 | LMNA (0.73) | LMNACHEK1MAPTTP53POLB | |
| SCHEMBL380110 | 0.81 | ALOX5 (0.61) | LMNAMAPTTP53POLBL3MBTL1 | |
| SCHEMBL3409888 | 0.81 | AHR (0.49) | LMNAMAPTTP53POLBL3MBTL1 | |
| SCHEMBL13929961 | 0.81 | MAPT (0.48) | LMNAMAPTTP53POLBL3MBTL1 | |
| SCHEMBL9270079 | 0.81 | CSNK1G1 (0.56) | LMNAMAPTTP53POLBL3MBTL1 | |
| SCHEMBL3835155 | 0.81 | MAPT (0.48) | LMNAMAPTTP53POLBL3MBTL1 | |
| SCHEMBL6045366 | 0.80 | ALOX5 (0.65) | LMNACHEK1MAPTTP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3997401-A | Microbial transformation of 8-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepine | G. D. SEARLE & CO. (US) | 1976-12-14 | — | — | US | claimed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| EP-2199295-A1 | COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-06-23 | — | — | EP | disclosed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-5602121-A | ANTISCHIZOPHRENIA AGENTS | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1997-02-11 | — | — | US | disclosed |
| US-5602120-A | ADMINISTERING FOR TREATING A CONDITION MEDIATED BY THE D4 RECEPTOR: SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1997-02-11 | — | — | US | disclosed |
| US-5576314-A | Bicyclic nonane and decane compounds having dopamine receptor affinity | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-11-19 | — | — | US | disclosed |
| US-5561127-A | TREATING ANXIETY, SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1996-10-01 | — | — | US | disclosed |
| WO-1996019479-A1 | MUSCARINIC RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-27 | — | — | WO | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |
| WO-1996018623-A1 | BENZYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1996018621-A1 | ALKYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| US-4086268-A | 2-(2-Amino-4-chlorophenoxy)benzyl alcohol and diacetate derivative | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | disclosed |
| US-3997401-A | Microbial transformation of 8-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepine | G. D. SEARLE & CO. (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | LMNA 4248/4885CHEK1 889/4885MAPT 2224/4885 |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | GPR119, CYP11B1, HSD11B1 | LMNA 2184/4885CHEK1 4701/4885MAPT 4246/4885 |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | LMNA 3338/4885CHEK1 2737/4885MAPT 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.